Systems Imagination has announced a partnership with Cofactor Genomics of St. Louis, Missouri, the market leader in RNA-based products and services in the rapidly expanding functional genomics market. This partnership combines Cofactor Genomics’ expertise in the generation of high quality genomic data with the big data analytics and unique knowledge mining services of SII.
Both companies focus on the highest quality data generation processes as well as innovative analytics to improve the recovery of useful and actionable biomedical data. Their efforts will result in an integrated service providing faster answers at a lower cost for pharmaceutical research. “We are really pleased to announce this important alliance with Cofactor,” commented Chris Yoo, Chief Executive Officer of Systems Imagination. “Our clients have been asking us to help them analyze data from ever more powerful molecular technologies like RNA-seq.
By partnering with Cofactor we can provide our customers with best-of-breed analytical research services that can generate the highest quality data required in performing translational studies of disease.” SII envisions that the collaboration will expand access to genomic profiling for pharmaceutical research companies that might not have the internal bandwidth or resources to conduct comprehensive genomic analyses for clinical drug development.
The collaboration between Systems Imagination and Cofactor Genomics will provide services that can provide scientific rationales for predicting patient response and guiding rational combination therapy through a new generation of systems biology. “It is a pleasure to contribute Cofactor’s expertise in all-things RNA to our partnership with SII.
Over the last five years, we have developed gold-standard molecular and quality control methods for RNA sequencing and data generation,” stated Jon Armstrong, Cofactor Genomics’ Chief Scientific Officer. “It is critical that the highest quality data enter SII’s analysis system for the generation of valuable, informative and interesting disease targets. Our partnership will allow researchers to extract valuable RNA insight that is only attainable with custom analysis solutions.”